Drug Shortage Report for AMIODARONE HYDROCHLORIDE FOR INJECTION, USP

Last updated on 2022-11-24 History
Report ID 168496
Drug Identification Number 02245248
Brand name AMIODARONE HYDROCHLORIDE INJECTION
Common or Proper name AMIODARONE HYDROCHLORIDE INJECTION
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) AMIODARONE HYDROCHLORIDE
Strength(s) 50MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 3 mL
ATC code C01BD
ATC description ANTIARRHYTHMICS, CLASS I AND III
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2022-08-02
Actual start date 2022-08-02
Estimated end date 2022-12-19
Actual end date
Shortage status Actual shortage
Updated date 2022-11-24
Company comments Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Amiodarone Hydrochloride for Injection 50 mg/mL MD Vial 3 mL effective November 1, 2022 until December 19, 2022.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v6 2022-11-24 French Compare
v5 2022-11-24 English Compare
v4 2022-09-12 French Compare
v3 2022-09-12 English Compare
v2 2022-09-01 French Compare
v1 2022-09-01 English Compare

Showing 1 to 6 of 6